New

Recombinant Non-Glycosylated Proteins Biosimilars Market

2021

Recombinant Non-Glycosylated Proteins Biosimilars Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Insulin, rHGH, Interferon); Application (Oncology, Blood Disorders, Chronic Diseases, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Diseases); and Geography

| Report Code: TIPRE00023146 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

Market Insights

Recombinant Non-Glycosylated Proteins Biosimilars Market 2028 By Product Type, Application, and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

A biosimilar is a biological product that is very similar to a biological marker and has no clinically significant differences in terms of security, purity, or potency. Human colony-stimulating granulocyte factor, growth hormone, insulin, and interferons are examples of non-glycosylated recombinant proteins. They're used in a variety of settings, including oncology, blood disorders, growth hormone deficiency, infectious disease, and more.

MARKET DYNAMICS

Factors such as increasing incidences of chronic disease, and rising demand for biosimilar will spur the demand for recombinant non-glycosylated proteins biosimilars market. Additionally, growing aging population and rapidly changing lifestyle and increasing urbanization will boost the market growth to significant extent over the forecast period. However, complexity associated with the manufacturing of biosimilar, and high R&D cost impede the growth of the market in the forecasted period.

MARKET SCOPE

The "Global Recombinant Non-Glycosylated Proteins Biosimilars Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of recombinant non-glycosylated proteins biosimilars market with detailed market segmentation by disease type, treatment type, diagnosis, end-user and geography. The global recombinant non-glycosylated proteins biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading recombinant non-glycosylated proteins biosimilars market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global recombinant non-glycosylated proteins biosimilars market is segmented into product type, and application. Based on product type, the global recombinant non-glycosylated proteins biosimilars market is segmented into recombinant human growth hormone (RHGH), insulin, interferon. Based on application, the global recombinant non-glycosylated proteins biosimilars market is segmented into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, other diseases.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global recombinant non-glycosylated proteins biosimilars market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The recombinant non-glycosylated proteins biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting recombinant non-glycosylated proteins biosimilars market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Recombinant non-glycosylated proteins biosimilars market in these regions.



Get more information on this report :

MARKET PLAYERS


The reports cover key developments in the recombinant non-glycosylated proteins biosimilars market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from recombinant non-glycosylated proteins biosimilars market are anticipated to lucrative growth opportunities in the future with the rising demand for recombinant non-glycosylated proteins biosimilars market in the global market. Below mentioned is the list of few companies engaged in the recombinant non-glycosylated proteins biosimilars market.

The report also includes the profiles of key recombinant non-glycosylated proteins biosimilars market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Sandoz International GmbH
  •   Celltrion Healthcare Co.,Ltd.
  •   Biocon
  •   Amgen Inc
  •   SAMSUNG
  •   Mylan N.V.
  •   Dr. Reddy's Laboratories Ltd.
  •   Stada Arzneimittel AG
  •   Pfizer Inc.
  •   Teva Pharmaceutical Industries Ltd

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Recombinant Non-Glycosylated Proteins Biosimilars Market - By Product Type
1.3.2 Recombinant Non-Glycosylated Proteins Biosimilars Market - By Application
1.3.3 Recombinant Non-Glycosylated Proteins Biosimilars Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET - GLOBAL MARKET ANALYSIS
6.1. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS - GLOBAL MARKET OVERVIEW
6.2. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. INSULIN
7.3.1. Overview
7.3.2. Insulin Market Forecast and Analysis
7.4. RHGH
7.4.1. Overview
7.4.2. rHGH Market Forecast and Analysis
7.5. INTERFERON
7.5.1. Overview
7.5.2. Interferon Market Forecast and Analysis
8. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. BLOOD DISORDERS
8.4.1. Overview
8.4.2. Blood Disorders Market Forecast and Analysis
8.5. CHRONIC DISEASES
8.5.1. Overview
8.5.2. Chronic Diseases Market Forecast and Analysis
8.6. AUTOIMMUNE DISEASES
8.6.1. Overview
8.6.2. Autoimmune Diseases Market Forecast and Analysis
8.7. GROWTH HORMONE DEFICIENCY
8.7.1. Overview
8.7.2. Growth Hormone Deficiency Market Forecast and Analysis
8.8. INFECTIOUS DISEASES
8.8.1. Overview
8.8.2. Infectious Diseases Market Forecast and Analysis
8.9. OTHER DISEASES
8.9.1. Overview
8.9.2. Other Diseases Market Forecast and Analysis
9. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
9.1.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis
9.1.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Product Type
9.1.4 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Application
9.1.5 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Countries
9.1.5.1 United States Recombinant Non-Glycosylated Proteins Biosimilars Market
9.1.5.1.1 United States Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.1.5.1.2 United States Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.1.5.2 Canada Recombinant Non-Glycosylated Proteins Biosimilars Market
9.1.5.2.1 Canada Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.1.5.2.2 Canada Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.1.5.3 Mexico Recombinant Non-Glycosylated Proteins Biosimilars Market
9.1.5.3.1 Mexico Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.1.5.3.2 Mexico Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.2. EUROPE
9.2.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
9.2.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis
9.2.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Product Type
9.2.4 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Application
9.2.5 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Recombinant Non-Glycosylated Proteins Biosimilars Market
9.2.5.1.1 Germany Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.2.5.1.2 Germany Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.2.5.2 France Recombinant Non-Glycosylated Proteins Biosimilars Market
9.2.5.2.1 France Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.2.5.2.2 France Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.2.5.3 Italy Recombinant Non-Glycosylated Proteins Biosimilars Market
9.2.5.3.1 Italy Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.2.5.3.2 Italy Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.2.5.4 Spain Recombinant Non-Glycosylated Proteins Biosimilars Market
9.2.5.4.1 Spain Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.2.5.4.2 Spain Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.2.5.5 United Kingdom Recombinant Non-Glycosylated Proteins Biosimilars Market
9.2.5.5.1 United Kingdom Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.2.5.5.2 United Kingdom Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
9.3.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis
9.3.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Product Type
9.3.4 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Recombinant Non-Glycosylated Proteins Biosimilars Market
9.3.5.1.1 Australia Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.3.5.1.2 Australia Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.3.5.2 China Recombinant Non-Glycosylated Proteins Biosimilars Market
9.3.5.2.1 China Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.3.5.2.2 China Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.3.5.3 India Recombinant Non-Glycosylated Proteins Biosimilars Market
9.3.5.3.1 India Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.3.5.3.2 India Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.3.5.4 Japan Recombinant Non-Glycosylated Proteins Biosimilars Market
9.3.5.4.1 Japan Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.3.5.4.2 Japan Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.3.5.5 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Market
9.3.5.5.1 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.3.5.5.2 South Korea Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
9.4.2 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis
9.4.3 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Product Type
9.4.4 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Recombinant Non-Glycosylated Proteins Biosimilars Market
9.4.5.1.1 South Africa Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.4.5.1.2 South Africa Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.4.5.2 Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Market
9.4.5.2.1 Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.4.5.2.2 Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.4.5.3 U.A.E Recombinant Non-Glycosylated Proteins Biosimilars Market
9.4.5.3.1 U.A.E Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.4.5.3.2 U.A.E Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Recombinant Non-Glycosylated Proteins Biosimilars Market Overview
9.5.2 South and Central America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis
9.5.3 South and Central America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Product Type
9.5.4 South and Central America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Application
9.5.5 South and Central America Recombinant Non-Glycosylated Proteins Biosimilars Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Recombinant Non-Glycosylated Proteins Biosimilars Market
9.5.5.1.1 Brazil Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.5.5.1.2 Brazil Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
9.5.5.2 Argentina Recombinant Non-Glycosylated Proteins Biosimilars Market
9.5.5.2.1 Argentina Recombinant Non-Glycosylated Proteins Biosimilars Market by Product Type
9.5.5.2.2 Argentina Recombinant Non-Glycosylated Proteins Biosimilars Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RECOMBINANT NON-GLYCOSYLATED PROTEINS BIOSIMILARS MARKET, KEY COMPANY PROFILES
12.1. SANDOZ INTERNATIONAL GMBH
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CELLTRION HEALTHCARE CO.,LTD.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BIOCON
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. AMGEN INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SAMSUNG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MYLAN N.V.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. DR. REDDY’S LABORATORIES LTD.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. STADA ARZNEIMITTEL AG
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Sandoz International GmbH
2. Celltrion Healthcare Co.,Ltd.
3. Biocon
4. Amgen Inc
5. SAMSUNG
6. Mylan N.V.
7. Dr. Reddy's Laboratories Ltd.
8. Stada Arzneimittel AG
9. Pfizer Inc.
10. Teva Pharmaceutical Industries Ltd
11. Boehringer Ingelheim GmbH
12. Momenta Pharmaceuticals
13. Eli Lilly and Company
14. Kyowa Kirin Biologics Co Ltd
15. LG Chem Ltd
TIPRE00023146
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.